IPM clocked 8446 Crs and grew at 3.5% in April 2016 - the lowest in last 2 years. April 2015 had growth of 17.9%
Companies:
In the top 10, Mankind grew at 12.3%, Abbott* at 9.9% followed by Macleods at 5.8%.
Only 21 companies crossed the growth of IPM for the month of April 2016 in the top 50
In the top 50, Bharat Serum had the highest growth of 25.2% followed by Systopic at 18.3% & Eris at 15.6%
Only 10 companies showed growth of more than 10% in the top 50
In the 11-20 ranked companies Intas had the highest growth of 10.8% followed by Micro*at 8.6% & USV at 5.1%
In the 21-30 ranked companies, Eris had the highest growth at 15.6% followed by Novartis at 12.1% & Wockhardt at 4.8%
In the 31-40 ranked companies, Bharat Serums grew at 25.2% followed by Akumentis at 11.8% and Wallace* at 11.0%
In the 41-50 ranked companies, Systopic had the highest growth at 18.3% followed by Janssen at 15.3% & Win-Medicare at 12.3%
In the 51-60 ranked companies, Boehringer grew at 58.7% followed by Fresenius Kabi at 29.2% & Corona at 19.0%
In the 61-70 ranked companies, Shreya grew at 37.8% followed by RPG at 15.7% and East India at 7.8%
In the 71-80 ranked companies, Samarth grew at 38.0% followed by Danone at 20.8% & Lincoln at 11.2%
In the 81-90 ranked companies, Dabur grew at 61.7% followed by Veritaz at 30.5% and by Galderma at 17.6%
In the 91-100 ranked companies, Ind-Swift grew at 67.2% followed by Sanzyme at 30.8% and Curatio at 27.0%
100th biggest company is Curatio and 150th biggest company is UTH in the IPM.
Abbott HC grew at 9.8% whereas Abbott India grew at 10.8% in April 2016.
Zuventus crossed 1000 Crs on MAT Basis to be at 1006 Crs as per April MAT 2016.
Indian V/s MNC
Indian companies grew at 3.6% versus 3.4% for MNCs
In the top 50 in MNCs, Janssen grew at 15.3% followed by Novartis at 12.1% and Abbott* at 9.9%
In the Non-NLEM category Indian companies grew at 4.6% whereas MNCs grew at 3.3%
NLEM, Non NLEM & Non-Scheduled Para 19 Market:
NLEM 2013 containing molecules market grew at -2.7% whereas the non DPCO market grew by 4.3 resulting in an overall growth of 3.5% for April 2016.
NLEM & Non - NLEM Category showed unit growth of -3.2% and -6.5% respectively.
Therapy Areas:
12 therapy areas have outgrown the IPM
Respiratory Market grew at -6.0%, Gastrointestinal market grew at 5.0% , Pain & Analgesics market grew at 0.7% whereas Anti-infectives grew at -3.5%
Anti-diabetic market grew at 12.1% & Cardiac at 7.4%, Neuro/ CNS at 9.0% in Chronic Business.
Anti-Malarials grew at -14.7%
Derma market grew by 7.1% & Urology at 10.4%.
Regional Dynamics:
17 regions have outgrown the IPM
Punjab market grew the highest at 12.9% followed by Haryana market at 9.1% & Saurashtra Market at 9.0%.
8 regions had negative growth in April 2016
Molecules:
Amoxycillin + Clavulanic Acid market grew at -4.9% & Glimepiride + Metformin Market grew at 10.6%
Paracetamol grew at 12.1%,
Atorvastatin 0.7%,
Probiotic Microbes at 25.6%,
Cefixime at -8.1%,
Pantoprazole at 8.5%,
Montelukast + Levocetrizine at -1.7%,
Glimepiride + Metformin + Pioglitazone at -19.2%,
Vitamin-D at 15.2%,
Hydroquinone + Mometasone + Tretinoin at -1.3%,
Voglibose + Metformin + Glimepiride at 32.6%,
Rosuvastatin at 12.2%, Protein Supplements at 5.8%,
Azithromycin at -10.1%,
Calcium Carbonate + Vit D3 market at -5.8%,
Paracetamol + Phenylephrine + Chlorpheniramine at -16.7%,
Meropenem at 37.2%,
Montelukast + Fexofenadine at 5.6%,
Diclofenac at 13.3%,
Telmisartan at 3.3%,
Levetiracetam at 20.5%
50th Biggest Market us Voglibose + Metformin + Glimepiride and 100th Biggest Market is Levofloxacin for Apr-16.
Brands:
Mixtard leads the with 36 Crs followed by Glycomet GP at 31 Crs, Corex at 28 Crs & Augmentin at 23 Crs.
Few Brands who have gained ranks include
Revital H (+2399),
Meronem (+94),
Rotarix (+73),
Trajenta (+59),
Januvia (+41),
Rabipur (+36),
Minipress XL (+34),
Ultracet (+30),
Udiliv, Novomox (+27),
Unwanted Kit (+26),
Galvus (+21),
Rosuvas, Mikacin, Vertin, Aciloc RD (+20),
Telma H (+19),
Electral Powder (+18),
Cardace (+16),
Duphaston (+15),
Galvus Met (+14),
Istamet (+13),
Atorva, Mucaine (+12),
Pan D, Allegra (+11),
Levipil (+10),
Synflorix, Jalra M (+9),
Lantus, Volini (+8),
Betadine, Pan, Gemer (+7),
Voveran, Susten (+6),
Corex, Rantac, Thyronorm,
Pantop (+5),
Clapol, Clexane (+4),
Zoryl M (+3), Dolo (+2)
Top 100 Brands over April – 15
Lonopin, Lobate GM, Razo D, Sporlac, Zerodol P, Candid, Mero, Acitrom, Metpure XL, Prega News, Telma AM, Cilacar, Enterogermina are few brands gained ranks in 101-200 ranked brands.
Few Brands that have moved up ranks fastest into Top 300 Brands for the month of April – 16 are Revital H, Hucog HP, Imicrit, Similac, Lonopin, Candiforce, Lobate GM, Orofer FCM, Razo D, Looz.
300th Biggest Brand is Pentaxim from Sanofi
New Launches in IPM:
Total 306 Brands & 489 SKUs launched in April 2016
Top New Brands for April -16 are Vivitra, Insta & Lomofen Plus
3 Brands Launched each in Teneligliptin Plain & in Combination with Metformin
Sanofi launches Gemigliptin under the Brand name Zemiglo
Within the VMS category, Jubinerv (Jubilant), PartySafe (Obsurge), Escor Z (Adroit)
in Anti-diabetic, Glyciphage VG (Franco), Tiban M (Ajanta) & Teneliglip (Akumentis).
In Derma, Itratuf (Alkem*), Kromalite (FDC) & Kezolin (FDC)
In Gynaec, Ovalife Met (Macleods) & Mychiro (USV)
In Pain & Analgesics Category we see Ostivestin, Candivestin (Zydus*), Dologesic SP (Micro*)
In Respiratory, Airlung FX (Zydus*), Kofirax ( Hetero), Newcold ML (Abbott*)
In Cardiac, Rozagold (Sun), Telmurix (Akesiss) & Roseday Gold (USV)
In Gastro Intestinal we see Novogermina (Alkem*), Acidart (Juggat), Fosaprepit ( Cipla)
Biggest New Launch by a MNC is Zemiglo from Sanofi.
SOURCE: AIOCD Pharmasofttech AWACS
Comments
Post a Comment